ALKS Insider Trading
Insider Ownership Percentage: 4.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $12,938,532.90
Alkermes Share Price & Price History
Current Price: $27.91
Price Change: ▲ Price Increase of +0.07 (0.25%)
As of 04/28/2025 05:00 PM ET
Alkermes Insider Trading History
Alkermes Institutional Trading History
Data available starting January 2016
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Read More on Alkermes
Today's Range
Now: $27.91
52 Week Range
Now: $27.91
Volume
1,517,298 shs
Average Volume
1,751,297 shs
Market Capitalization
$4.60 billion
P/E Ratio
12.86
Dividend Yield
N/A
Beta
0.39
Who are the company insiders with the largest holdings of Alkermes?
Who are the major institutional investors of Alkermes?
Alkermes' top institutional shareholders include:
- Principal Financial Group Inc. — 0.56%
- Rhumbline Advisers — 0.28%
- GAMMA Investing LLC — 0.11%
- Wedge Capital Management L L P NC — 0.07%
- State of Alaska Department of Revenue — 0.05%
- New York State Teachers Retirement System — 0.05%
Learn More about top institutional investors of Alkermes stock.
Which institutional investors are selling Alkermes stock?
During the last quarter, ALKS stock was sold by these institutional investors:
- Robeco Institutional Asset Management B.V.
- Allspring Global Investments Holdings LLC
- Assenagon Asset Management S.A.
- Rhumbline Advisers
- Vontobel Holding Ltd.
- Exchange Traded Concepts LLC
- Teacher Retirement System of Texas
- Wealth Enhancement Advisory Services LLC
Within the last year, company insiders that have sold Alkermes company stock include:
- Craig C Hopkinson (EVP)
- Christian Todd Nichols (SVP)
- Cato T Laurencin (Director)
Learn More investors selling Alkermes stock.
Which institutional investors are buying Alkermes stock?
During the last quarter, ALKS stock was purchased by institutional investors including:
- GAMMA Investing LLC
- Advisor Resource Council
- Principal Financial Group Inc.
- Private Client Services LLC
- Ritholtz Wealth Management
- Avanza Fonder AB
- Pallas Capital Advisors LLC
- Wedge Capital Management L L P NC